The DOI matches its Crossref record; 175 of the 175 references it cites were found in a registry or an index.
Endometriosis: Current Therapies and New Pharmacological Developments
Abstract
Endometriosis is a chronic inflammatory condition that is responsive to management with steroids. The establishment of a steady hormonal environment and inhibition of ovulation can temporarily suppress ectopic implants and reduce inflammation as well as associated pain symptoms. In terms of pharmacological management, the currently available agents are not curative, and treatment often needs to be continued for years or until pregnancy is desired. Similar efficacy has been observed from the various therapies that have been investigated for endometriosis. Accordingly, combined oral contraceptives and progestins, based on their favourable safety profile, tolerability and cost, should be considered as first-line options, as an alternative to surgery and for post-operative adjuvant use. In situations where progestins and oral contraceptives prove ineffective, are poorly tolerated or are contraindicated, gonadotrophin-releasing hormone analogues, danazol or gestrinone may be used. Future therapeutic options for managing endometriosis must compare favourably against existing agents before they can be considered for inclusion into current practice. Finally, as reproductive prognosis is not ameliorated by medical treatment, it is not indicated for women seeking conception.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Irregular uterine bleeding is a known common adverse effect of all long-term progestin treatments [8].”
From Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment (2012) · cites this paper as [8]
In the citing paper
“Progestins are a recommended treatment for the pain associated with endometriosis, but a number of agents in this class are associated with androgenic effects and weight gain at the doses that are required for efficacy [8].”
From Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment (2012) · cites this paper as [8]
In the citing paper
“Norethisterone acetate is a potent progestin derivative of 19-norethisterone and is valid for use in patients with endometriosis [8]; however, its main side effects include breast tenderness, weight gain, acne and hirsutism, in addition to breakthrough bleeding.”
From Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment (2012) · cites this paper as [8]
Citations
Cites
Revised American Fertility Society Classification of Endometriosis: 1985
(1985) · Fertility and Sterility · doi:10.1016/s0015-0282(16)48430-x · Cited by 1,803
ESHRE guideline for the diagnosis and treatment of endometriosis
Kennedy, S., Bergqvist, A., Chapron, C., D’Hooghe, T., Dunselman, G., Greb, R., Hummelshoj, L., Prentice, A., & Saridogan, E. (2005) · Human Reproduction · doi:10.1093/humrep/dei135 · Cited by 1,584 · cited 2×
“For the purposes of this review, we address only the management of pain because it has been shown that medical therapy does not impact on fertility, either when used alone or as a post-operative adjuvant measure.([3-5]) Conversely, the efficacy of hormonal drugs on endometriosisassociated algic symptoms has been defin…”
Assessment of menstrual blood loss using a pictorial chart
HIGHAM, J. M., O'BRIEN, P. M. S., & SHAW, R. W. (1990) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.1990.tb16249.x · Cited by 1,116 · cited 1×
“Monthly blood loss assessed by the semiquantitative pictorial blood loss assessment chart (PBAC) score([47]) varied from 204 – 196 at evaluation prior to insertion of the levonorgestrelIUS to 90– 157 at 6 months post-insertion (a score of >100 is suggestive of menorrhagia).”
Immunobiology of endometriosis
Lebovic, D. I., Mueller, M. D., & Taylor, R. N. (2001) · Fertility and Sterility · doi:10.1016/s0015-0282(00)01630-7 · Cited by 857
Bulletti, C., Coccia, M. E., Battistoni, S., & Borini, A. (2010) · Journal of Assisted Reproduction and Genetics · doi:10.1007/s10815-010-9436-1 · Cited by 758
Vascular endothelial growth factor (VEGF) in endometriosis
Donnez, J., Smoes, P., Gillerot, S., Casanas-Roux, F., & Nisolle, M. (1998) · Human Reproduction · doi:10.1093/humrep/13.6.1686 · Cited by 531 · cited 2×
“VEGF immunostaining has been observed in the epithelium of endometriotic implants, particularly in hemorrhagic red implants.([167]) Elevated levels of VEGF-A have also been demonstrated in peritoneal fluid from women with endometriosis; the highest levels were seen during the proliferative phase of the cycle, a time a…”
Petta, C. A., Ferriani, R. A., Abrao, M. S., Hassan, D., Rosa e Silva, J. C., Podgaec, S., & Bahamondes, L. (2005) · Human Reproduction · doi:10.1093/humrep/deh869 · Cited by 363 · cited 4×
“Petta et al.[49] compared the efficacy of the levonorgestrel-IUS (n = 39) with leuprorelin depot 3.75mg/28 days (n = 43) for control of endometriosis-related pain, in a 6-month randomized, controlled, multicentre trial.”
InfluentialAdministration of Nasal Nafarelin as Compared with Oral Danazol for Endometriosis
Henzl, M. R., Corson, S. L., Moghissi, K., Buttram, V. C., Berqvist, C., & Jacobson, J. (1988) · New England Journal of Medicine · doi:10.1056/nejm198802253180805 · Cited by 361
McLaren, J., Prentice, A., Charnock-Jones, D. S., & Smith, S. K. (1996) · Human Reproduction · doi:10.1093/oxfordjournals.humrep.a019023 · Cited by 350
Long-term pituitary down-regulation before in vitro fertilization (IVF) for women with endometriosis
Sallam, H. N., Garcia-Velasco, J. A., Dias, S., Arici, A., Abou-Setta, A. M., & Jaafar, S. H. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004635.pub2 · Cited by 349
Research works printed but not linked: 21
- 2006, Fertil Steril, 86, S156
- Muneyyirci-Delale, 1998, Int J Fertil Womens Med, 43, 24
- Moore, 1999, Drugs Today, 35, 41
- Fedele, 1989, Obstet Gynecol, 73, 1000
- Moran, 1996, Arch Med Res, 27, 535
- Bergqvist, 2001, Acta Obstet Gynecol Scand, 80, 628, 10.1080/j.1600-0412.2001.800708.x · DOI
- Reimnitz, 1988, Obstet Gynecol, 71, 444
- Lavery, 2001, BJOG, 108, 1106
- Gücer, 1998, Eur J Gynaecol Oncol, 19, 39
- Oxholm, 2007, Acta Obstet Gynecol Scand, 4, 1
- Davis, 2007, Cochrane Database Syst Rev, 3, CD001019
- Prentice, 2007, Cochrane Database Syst Rev, 3, CD000346
- Surrey, 2002, Obstet Gynecol, 99, 709
- Yap, 2004, Cochrane Database Syst Rev, 3, CD003678
- Sallam, 2006, Cochrane Database Syst Rev, 1, CD004635
- Rotondi, 2002, Eur J Gynaecol Oncol, 23, 523
- Selak, 2001, Cochrane Database Syst Rev, 4, CD000068
- Viganò, 2003 Oct, Curr Opin Investig Drugs, 4, 1209
- Holcombe, 2001, Cancer Detect Prev, 25, 183
- Badawy, 2001, Obstet Gynecol, 98, 417
- Lev-Ari, 2008 Jan, Recent Pat Anticancer Drug Discov, 3, 55
Cited by
Endometriosis: pathogenesis and treatment
Vercellini, P., Viganò, P., Somigliana, E., & Fedele, L. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.255 · Cited by 1,940
Self-citationEndometriosis and infertility: pathophysiology and management
de Ziegler, D., Borghese, B., & Chapron, C. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60490-4 · Cited by 843
Contemporary genetic technologies and female reproduction
The Evian Annual Reproduction (EVAR) Workshop Group 2010, Fauser, B. C. J. M., Diedrich, K., Bouchard, P., Dominguez, F., Matzuk, M., Franks, S., Hamamah, S., Simon, C., Devroey, P., et al. (2011) · Human Reproduction Update · doi:10.1093/humupd/dmr033 · Cited by 349
Clinical Management of Endometriosis
Falcone, T., & Lebovic, D. I. (2011) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e31822adfd1 · Cited by 263
Estrogen-progestins and progestins for the management of endometriosis
Vercellini, P., Buggio, L., Berlanda, N., Barbara, G., Somigliana, E., & Bosari, S. (2016) · Fertility and Sterility · doi:10.1016/j.fertnstert.2016.10.022 · Cited by 243
Self-citation
Metadata
- Authors
- Vercellini, P., Somigliana, E., Viganò, P., Abbiati, A., Barbara, G., & Crosignani, P. G.
- Affiliations
- University of Milan (IT)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- IRCCS Ospedale San Raffaele (IT)
- Corresponding author
- Vercellini, Paolo
- Venue
- Drugs
- Published
- 2009
- Volume
- 69
- Issue
- 6
- Pages
- 649-675
- ISSN
- 0012-6667 (ISSN-L)
- OpenAlex
- W2077356215
- Cited by
- 182
- References
- 175
- Citations by year
- 2026: 8 · 2025: 6 · 2024: 7 · 2023: 20 · 2022: 2 · 2021: 6 · 2020: 8 · 2019: 8 · 2018: 8 · 2017: 8 · 2016: 6 · 2015: 12 · 2014: 14 · 2013: 7 · 2012: 13
- FWCI
- 2.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Health Sciences › Medicine › Obstetrics and Gynecology › Ectopic Pregnancy Diagnosis and Management
- Health Sciences › Medicine › Obstetrics and Gynecology › Gynecological conditions and treatments
- Keywords
- endometriosis, medical management, combined oral contraceptives, progestins, GnRH analogues, danazol, gestrinone, ovulation inhibition, hormonal suppression, chronic inflammation, fertility preservation
- MeSH terms
- Clinical Trials as Topic, Danazol, Drug Therapy, Endometriosis, Estrogens, Female, Gestrinone, Humans, Gonadotropin-Releasing Hormone, Progestins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Endometriosis: Current Therapies and New Pharmacological Developments. https://app.cochat.ai/papers/10.2165/00003495-200969060-00002
- The paper
- Vercellini, P., Somigliana, E., Viganò, P., Abbiati, A., Barbara, G., & Crosignani, P. G. (2009). Endometriosis: Current Therapies and New Pharmacological Developments. Drugs. https://doi.org/10.2165/00003495-200969060-00002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.